Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Saint Priest En Jarez – page 59

1 694 clinical trials in Saint Priest En Jarez, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint Priest En Jarez at a glance
1 694
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 694 trials in Saint Priest En Jarez

Open in trial search

Renal transplant+1

Not yet recruiting

Effect of Continuing Tacrolimus on Access to a Second Kidney Transplant in Patients with Renal Transplant Failure: A Randomized Controlled Trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:University Hospital Of Clermont-Ferrand

C3 glomerulopathy

Not yet recruiting

Pegcetacoplan to Prevent Recurrence of C3 Glomerulopathy or Primary Immune‑Complex MPGN in Adolescent and Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Colorectal cancer

Not yet recruiting

A phase 1/2 study evaluating safety, pharmacokinetics and efficacy of SOT109 in patients with advanced unresectable or metastatic colorectal cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:SOTIO Biotech a.s.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Epilepsy

Not yet recruiting

Efficacy of fluoxetine added to standard anti‑seizure therapy in children aged 8 years and older with drug‑resistant complex and rare epilepsy

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Fluoxetine
  • Sponsor:Assistance Publique Hopitaux De Marseille

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Not yet recruiting

Ivonescimab with drug combination in patients with asymptomatic brain metastases from non‑small cell lung cancer – randomized phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of epcoritamab, venetoclax and ibrutinib in treatment‑naïve chronic lymphocytic leukemia patients with TP53 alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:LYSARC

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Saint Priest En Jarez

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on head and neck cancer, multiple myeloma, and acute myeloid leukemia. Studies evaluating novel therapeutic approaches including targeted treatments and combination therapies.

  • Head & Neck Squamous Cell Carcinoma
  • Multiple Myeloma Treatment
  • Pancreatic Adenocarcinoma

Investigating breakthrough treatments and improving patient outcomes through innovative therapeutic strategies.

02 Autoimmune Disorders

Comprehensive research into inflammatory conditions and autoimmune diseases, with particular focus on Crohn's disease, rheumatoid arthritis, and novel treatment approaches.

  • Psoriatic Arthritis
  • Ulcerative Colitis
  • Sjögren's Syndrome

Evaluating advanced therapies and treatment combinations to improve disease management and patient quality of life.

03 Cardiovascular & Pulmonary Studies

Innovative research in pulmonary arterial hypertension and related conditions, exploring new therapeutic options and treatment strategies.

  • Pulmonary Hypertension
  • Chronic Kidney Disease
  • Cardiovascular Complications

Testing novel compounds and therapeutic approaches to address complex cardiovascular and pulmonary conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.